References
- GPCaviglia, SPantaleoni, GATouscoz, AAdriani, CRosso, ASmedile, et al. Fecal calprotectin is an effective diagnostic tool that differentiates inflammatory from functional intestinal disorders. Scand J Gastroenterol 2014;49:1419–24.
- FJVerdam, SFuentes, Cde Jonge, EGZoetendal, RErbil, JWGreve, et al. Human intestinal microbiota composition is associated with local and systemic inflammation in obesity. Obesity (Silver Spring) 2013;21:E607–15.
- JBrignardello, PMorales, EDiaz, JRomero, OBrunser, MGotteland. Pilot study: alterations of intestinal microbiota in obese humans are not associated with colonic inflammation or disturbances of barrier function. Aliment Pharmacol Ther 2010;32:1307–14.
- SCarnahan, ABalzer, SKPanchal, LBrown. Prebiotics in obesity. Panminerva Med 2014;56:165–75.
- BMoum, JJahnsen, TBernklev. Fecal calprotectin variability in Crohn’s disease. Inflamm Bowel Dis 2010;16:1091–2.
- ALasson, P-OStotzer, LOhman, SIsaksson, MSapnara, HStrid. The intra-individual variability of faecal calprotectin: a prospective study in patients with active ulcerative colitis. J Crohns Colitis 2015;9:26–32.